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Abstract
The first, long-awaited, structures of non-visual G-protein-coupled receptors have provided
important insights into the process of ligand binding and receptor activation. Here I explore the
technological advances that enabled the resolution of the crystal structures of the b1- and
b2-adrenergic receptors, and review what we have learnt and what is still to be discovered.
Introduction and context
G-protein-coupled receptors (GPCRs) are a little like
the famous red London buses; you wait years for a
structure and when one at last arrives it is quickly
followed by many. Seven years after the pioneering work
on the rhodopsin structure by Palczewski et al. [1], the
race for the first crystal structure of a non-visual GPCR
has been won by research teams led by Brian Kobilka
and Raymond Stevens working on the b2-adrenergic
receptor [2–4].
Why did it take so long and require such a huge
international effort, and the development of numerous
novel technologies, to arrive at a structure that was so
highly prized by both academia and the pharmaceutical
industry? This can essentially be explained by the fact
that unlike rhodopsin, which forms a highly stable
inactive conformational state, non-visual GPCRs adopt
numerous conformational states even when they are
considered to be inactive [5]. Such heterogeneity of
conformation is not conducive to the formation of
diffraction-quality crystals. Hence, ironically, the very
characteristic of GPCRs that gives rise to complex
pharmacology and an ability to regulate numerous
biological processes, namely their conformational flex-
ibility, is the primary characteristic that has hindered
crystallisation and resolution of their structure. I will
cover here the key factors that allowed the first structural
determination of a non-visual GPCRs, and the major
findings from these studies. There are also a number of
excellent recent reviews to which the reader is directed for
further analysis [6–10].
Technological advances
The b2-adrenergic receptor, activated by the natural
ligands adrenaline and noradrenaline, is of biomedical
importance because of its cardiovascular and pulmonary
function. However, it was the detailed pharmacological
knowledge and biochemical expertise gathered over
decades of investigation that made this receptor a more
attractive proposition for crystallisation than any of the
other ~800 GPCRs. Technology developed more than
20 years ago for the purification of the b-adrenergic
receptor from frog erythrocytes [11] – the first biochem-
ical purification of a GPCR – provided the first step in
the crystallisation process. Affinity-chromatography
columns immobilising the receptor antagonist
alprenolol enabled purification of the receptor such
that nearly 100% of the receptors were functionally
active [3]. In comparison, purification of the receptor
using a resin-bound antibody against an amino (N)-
terminal FLAG epitope tag resulted in highly purified
receptor, but less than 50% of the purified receptor was
able to bind ligand [3]. Importantly, the ligand-affinity-
purified receptor adopted a highly stable conformation if
maintained in the presence of an antagonist. Under these
conditions, solutions containing receptor concentrations
of ~50 mg/ml were stable for up to a week at room
temperature [3].
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antagonist to use in the stabilisation of the receptor.
Carazolol was chosen, as it has picomolar affinity for the
receptor and very slow dissociation kinetics. Further-
more, carazolol is an inverse agonist and so is able to
reduce the constitutive activity of the receptor by driving
the equilibrium towards an inactive conformation. The
proportion of receptors adopting a totally inactive
conformation in the presence of carazolol would there-
fore be high, thus reducing the conformational hetero-
geneity that might otherwise prevent crystal formation.
It would seem that purification of functional receptor to
high concentrations coupled with stabilisation of the
receptor with antagonists would be sufficient to allow
successful crystallisation. However, despite more than
2000 conditions being tested at different temperatures,
diffraction-quality crystals were not obtained [3]. There
still appeared to be conformational heterogeneity, and
the receptor domains responsible for this were likely to
be the flexible intracellular carboxy (C)-terminal tail and
third intracellular loop [12]. In the two published
structures of the b2-adrenergic receptor, the teams led
by Kobilka and Stevens tackled the flexibility of the
C-terminal tail in the same way, namely by truncating
this domain. However, each handled the problem of the
flexibility of the third intracellular loop using different
approaches. One was to use a conformation-specific
antibody against the third intracellular loop to 'lock' the
loop into a fixed conformation in a manner that did not
affect the ligand-binding site (as judged by the pharma-
cological characteristics of ligand binding) [3]. This
approach had previously been used to obtain the
structure of a K
+ channel at a resolution of 2.0 Å [13].
The other approach was to replace the third intracellular
loop with T4 lysozyme, which is a highly ordered protein
that readily forms crystals [2,4]. Both approaches
effectively resulted in the same outcome, namely the
removal of the most flexible regions of the receptor and
their replacement with a highly ordered protein (anti-
body Fab fragment or T4 lysozyme), which in itself will
form good crystals.
Another hurdle to overcome was the fact that GPCRs are
highly hydrophobic proteins with seven helical domains
that transverse the plasma membrane. It was therefore
necessary to solubilise the receptor, and the detergent
conditions used to achieve this must maintain the
receptor in a native conformation and be conducive to
crystallisation. This was achieved for the b2-adrenergic
receptor by using either a cholesterol-doped monolein
lipid cubic phase [2,4] or bicelles composed of the lipid
dimyristoyl phosphatidylcholine and the detergent
CHAPSO (DMPC/CHAPSO) [3].
Hence, by combining biochemical purification techni-
ques, pharmacological stabilisation, protein engineering,
antibody technology and lipid chemistry, crystals of the
b2-adrenergic receptor were obtained. These were, how-
ever, tiny – no more than 30 μm across and 10 μm thick
[2,4]. Conventional X-ray beams are 50 μm wide and
were therefore unable to resolve these crystals, which
were also readily destroyed in the beam. The final piece
in the jigsaw was the application of high-intensity X-ray
microbeams of less than 10 μm diameter. The applica-
tion of this technology finally revealed structures of the
b2-adrenergic receptor at 2.4 Å [2,4] and 3.4/3.7 Å [3]
resolution.
Major recent advances
Overall structure
Until the publication of the b2-adrenergic receptor
structures, the conformation of GPCRs had been
modelled on that of rhodopsin [14]. The first question,
naturally, was how did the structure of the b2-adrenergic
receptor, which like rhodopsin is a class A GPCR, match
the structure of rhodopsin? The answer is that overall
there is a strong structural similarity between the two
proteins. This is measured empirically by the root-mean-
square (rms) deviation between the two structures,
which for the transmembrane helical domains is 1.6 Å
and for the whole receptor is 2.3 Å. This is considered to
represent very close structural similarity, as illustrated,
for example, by a comparison of the closely related
protein kinase catalytic domains of the enzymes PKC
and PKA, which have an rms of 2.3 Å but where the
sequence identity is higher (31%) than it is between b2-
adrenergic receptor and rhodopsin transmembrane
domains (23%) [8].
Second extracellular loop
Whereas the overall topography of the helical domains
of the b2-adrenergic receptor and rhodopsin are similar,
the subtle differences seen between the two structures
reveal something of the processes of ligand binding and
receptor activation (Figure 1). In terms of ligand binding,
the most striking feature is the position of the second
extracellular loop (ECL2), which in rhodospin folds into
a b sheet that is buried within the helical transmembrane
domains. Together with N-terminal interactions, the
buried ECL2 of rhodopsin forms a lid over the retinal-
binding pocket protecting cis-retinal from hydrolysis. If
such an arrangement were to occur in the b2-adrenergic
receptor, it would severely restrict access of ligands to the
ligand-binding pocket. Instead, in the b2-adrenergic
receptor, the ECL2 forms a short helix that is constrained
by two disulphide bonds. In this arrangement, the ECL2
of the b2-adrenergic receptor is held away from the
ligand-binding pocket. Furthermore, through the
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cellular loop, the ECL2 forms a rigid structure that
stabilises the core of the receptor. The recent resolution
of the b1-adrenergic receptor structure shows a similar
conformation of the ECL2 [15], suggesting that this
feature may be common among non-visual class A
GPCRs (Figure 2).
The ionic lock
The second surprising structural feature is centred on the
network of ionic and hydrogen-bond interactions
between the conserved (D/E)R(Y/W) amino-acid motif
found atthecytoplasmic endofthethird transmembrane
domain (TM3) andresiduesatthe cytoplasmic end of the
sixth transmembrane domain (TM6). These interactions,
knownas the'ioniclock', wereobservedintherhodopsin
structure [1] and are thought to stabilise the inactive
conformation of the majority of class A receptors by
linking the cytoplasmic ends of TM3 and TM6. Fluor-
escent spectroscopy techniques have found changes in
the conformation of the ionic lock during activation of
the receptor by agonists [16], supporting the notion that
opening the structure of the ionic lock is important in
receptor activation [5]. This notion is further supported
by the recent crystal structure of ligand-free opsin, which
adoptsanactiveconformationandwheretheioniclockis
open [17]. Surprisingly, both structures of the b2-
adrenergic receptor revealed that the ionic lock was in
theopenconformation,astatepreviouslyassociatedwith
the active receptor. This was unexpected, as the receptor
was crystallised in the presence of the inverse agonist
carazolol, which should maintain it in an inactive
conformation. It is possible that carazolol, which in fact
onlyreducesb2-adrenergicreceptorbasalactivityby50%,
does not maintain the receptor in a completely inactive
conformation [3]. Therefore, the structure of the b2-
adrenergic receptor obtained in the presence of carazolol
may represent a partially active conformation in which
the ionic lock is open [3].
Recent resolution of the b1-adrenergic receptor structure
has, however, brought into question the original inter-
pretation of the ionic lock. A thermostable mutant of the
turkey b1-adrenergic receptor was crystallised in the
presence of the antagonist cyanopindolol [15]. Signal-
ling assays established that the receptor had no basal
activity and was therefore in a totally inactive state. The
crystal structure of this receptor revealed that, like the b2-
adrenergic receptor, the ionic lock was in the open
conformation. The authors of the b1-adrenergic receptor
structure suggest that the ionic lock is not important for
the stabilisation of the inactive state of non-visualGPCRs
and even suggest that this may also be the case for
rhodopsin [15].
The rotamer toggle
The ionic lock is one of two molecular switches that have
been proposed to operate during agonist activation of
Figure 1. Structures of the b2-adrenergic receptor
The structures of the b2-adrenergic receptor determined by stabilisation
using (a) the Fab fragment of a conformation-specific antibody
(b2-adrenergic-Fab) and (b) the b2-adrenergic receptor-T4 lysozyme fusion
protein (b2-adrenergic-T4). The structures (a) and (b) were kindly created
for this commentary by Brian Kobilka, Stanford University.
Figure 2. Structure of the b1-adrenergic receptor
Shown is the recent structure of the b1-adrenergic receptor. Figure 2 was
kindly provided by Gerbhard Schertler, Laboratory of Molecular Biology,
University of Cambridge.
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rearrangements made possible by a series of conserved
prolines within the transmembrane domains that
introduce kinks into the helices. Of particular impor-
tance is the highly conserved proline kink in TM6, which
in the b2-adrenergic receptor is located at Pro288. The
angle of the kink induced by Pro288 is dependent on
interactions with aromatic residues close by (Trp286,
Phe289, Phe290). Agonist binding promotes rotation of
the aromatic residues and modulation of the angle of the
proline kink in a process referred to as a 'rotamer toggle'
[18,19].
Although carazolol does not interact directly with
Pro288, it does interact with the aromatic amino acids
of the rotamer toggle, which adopt a rotameric state
associated with the inactive receptor [2]. Importantly, the
rotamer toggle is also associated with a series of water
molecules that form a hydrogen-bonding network
extending from the transmembrane helical bundle to
the cytoplasmic surface [2]. It is possible that this
network, which interacts with a number of highly
conserved amino acids, is important in transmitting
structural changes from the ligand-binding pocket to
distal sites.
Future directions
The currently available structures of the b1- and b2-
adrenergic receptors represent enormous effort and
ingenuity, and provide invaluable information regarding
the nature of the receptor ligand-binding site and
mechanisms of activation. However, they have serious
limitations. First, the structures obtained are not of the
native receptors but of highly engineered proteins. More
important, however, is the fact that crystal structures will
only give information about one conformation of the
receptor. Because active receptor conformations are likely
to be heterogeneous, with the receptor adopting multiple
conformational states [5,20], it may be that a crystal
structure of an active receptor is not possible, or at least
extremely difficult, to obtain. The first structure of an
active GPCR – that of a photoactivated rhodopsin – has
recently been published [21]. Nevertheless, other bio-
physical techniques that can more readily identify
conformational change, such as site-directed spin label-
ling, may prove more informative [22]. Great hope has
also been placed on the application of NMR to resolve
the structural changes following agonist, antagonist and
allosteric modulator binding [5].
So what can we expect from X-ray crystallography in the
future? Certainly we can expect many more structures
and more surprises. The recently reported structure of
squid rhodopsin, for example, represents the first
structure of a Gq-coupled GPCR [23]. The most
pronounced feature of this receptor is that the trans-
membrane helices V and VI extend into the cytoplasm
and combine with a helix in the extended C-terminal tail
to form a rigid structure in the cytoplasm that has been
called the helical dome [24]. This structure is thought to
play a part in Gq-protein coupling. We will have to wait
to see if similar structures are determined for vertebrate
Gq-coupled GPCRs. What is certain, however, is that this
pioneering work will continue to reveal how changes in
the structure of this superfamily of transmembrane
receptor proteins can mediate the plethora of biological
responses that have been attributed to GPCR activity.
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